 GlaxoSmithKline and Pfizer will hold out for a better bid of at least 60 billion for their joint consumer healthcare venture, in opposition to an earlier offer they didnt like, Financial Times writes. Theyre rejecting a 50 billion offer from Unilever, which GSK said was fundamentally undervalued. 